CACNA1F

Voltage-dependent L-type calcium channel subu · O60840 · CACNA1F on Sugi Atlas →

73,158 patent compounds predicted against CACNA1F, 49,566 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL116362	0.45	11/20
Nisoldipine (SCHEMBL39779)	1.00	9/20
Nisoldipine (SCHEMBL39780)	1.00	9/20
Nitrendipine (SCHEMBL38972)	0.91	9/20
(R)-Nitrendipine (SCHEMBL38973)	0.91	9/20
(S)-Nitrendipine (SCHEMBL120983)	0.91	9/20
Nimodipine (SCHEMBL34041)	0.82	8/20
(S)-Nimodipine (SCHEMBL34042)	0.82	8/20
Nimodipine (SCHEMBL142534)	0.81	8/20
SCHEMBL194784	0.51	8/20
Cilnidipine (SCHEMBL25550)	0.69	7/20
Cilnidipine (SCHEMBL25551)	0.69	7/20
SCHEMBL25549	0.62	7/20
SCHEMBL265956	0.48	5/20
SCHEMBL66633	0.42	5/20
Difluanine (SCHEMBL124263)	0.54	4/20
SCHEMBL202396	0.51	4/20
Lidoflazine (SCHEMBL79037)	0.51	4/20
SCHEMBL105960	0.50	4/20
SCHEMBL301540	0.42	4/20

Clinical trials — most relevant to CACNA1F by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination	PHASE4	UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	PHASE3	COMPLETED
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients	PHASE2	WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients	PHASE2	WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain	PHASE2	COMPLETED
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED
Physiologic Effects of Topiramate on Cognition	PHASE1	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Evaluation of A Clinical Diagnostic Test for CRDS	nan	RECRUITING
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
International CRDS Registry	nan	RECRUITING
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
Verapamil in Supraclavicular Brachial Plexus Block	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
The Use of Antiarrhythmic Drugs in Pediatrics	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors	nan	UNKNOWN
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism	nan	COMPLETED
The Prevalence of RYR1-related Disease	nan	NOT_YET_RECRUITING
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia	nan	COMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	nan	RECRUITING
A Natural History Study of RYR1-Related Disorders	nan	RECRUITING
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Comparison of the Effects of Dexmedetomidine and Lidocaine on Blood Pressure and Heart Rate Response	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNA1F binder may also engage these)

Protein	Name	Similarity
Q9JIS7	—	1.000	Q9JIS7 →
Q02789	—	0.993	Q02789 →
CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	0.991	landscape →
P27732	—	0.990	P27732 →
P07293	—	0.990	P07293 →
O57483	—	0.990	O57483 →
Q05152	—	0.990	Q05152 →
CACNA1I	Voltage-dependent T-type calcium channel subunit alpha-1I	0.989	landscape →
CACNA1G	Voltage-dependent T-type calcium channel subunit alpha-1G	0.989	landscape →
CACNA1D	Voltage-dependent L-type calcium channel subunit alpha-1D	0.989	landscape →
CACNA1C	Voltage-dependent L-type calcium channel subunit alpha-1C	0.988	landscape →
O73700	—	0.988	O73700 →
P22002	—	0.988	P22002 →
P15389	—	0.987	P15389 →
O54898	—	0.987	O54898 →
Q9Z0Y8	—	0.987	Q9Z0Y8 →
SCN5A	Sodium channel protein type 5 subunit alpha	0.986	landscape →
C9D7C2	—	0.986	C9D7C2 →
P15381	—	0.986	P15381 →
Q02294	—	0.985	Q02294 →
SCN10A	Sodium channel protein type 10 subunit alpha	0.985	landscape →
Q99244	—	0.985	Q99244 →
P22316	—	0.985	P22316 →
Q62968	—	0.985	Q62968 →
Q61290	—	0.985	Q61290 →
P54282	—	0.985	P54282 →
P17659	—	0.985	P17659 →
Q9JJV9	—	0.985	Q9JJV9 →
Q02485	—	0.985	Q02485 →
Q07652	—	0.984	Q07652 →